Abstract
Angiogenesis is now a validated target in advanced colorectal cancer (CRC), with three agents (bevacizumab, aflibercept, and regorafenib) now available in clinical practice as part of first-, second-, and later-line therapy. Continued suppression of the vascular endothelial growth factor (VEGF) pathway into serial lines of therapy in CRC has been validated in clinical trials. An alternative approach that directly targets the VEGF receptor 2 …
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call